Ixekizumab Improved Refractory Erythrodermic Psoriasis with Comorbid Diffuse Alopecia: A Case Report with 52-Week Follow-Up

Biao Song,1– 3,&ast; Xiaohan Liu,1– 3,&ast; Hongzhong Jin1– 3 1Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People’s Republic of China; 2State Key Laboratory of Complex Severe and Rare Diseases...

Full description

Bibliographic Details
Published in:	Clinical, Cosmetic and Investigational Dermatology
Main Authors:	Song B, Liu X, Jin H
Format:	Article
Language:	English
Published:	Dove Medical Press 2024-08-01
Subjects:	erythrodermic psoriasis alopecia ixekizumab
Online Access:	https://www.dovepress.com/ixekizumab-improved-refractory-erythrodermic-psoriasis-with-comorbid-d-peer-reviewed-fulltext-article-CCID

Similar Items

Adalimumab-Induced Erythrodermic Psoriasis Associated with Alopecia in a Patient with Palmoplantar Pustulosis
by: Ying Wang, et al.
Published: (2024-04-01)

Biologic anti-IL17 drugs in erythrodermic psoriasisCapsule Summary
by: Alessandro Falco, MD, et al.
Published: (2024-09-01)

Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series
by: Andrea D'Arino, et al.
Published: (2025-07-01)

A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab
by: Megna M, et al.
Published: (2023-12-01)

Erythrodermic Psoriasis Managed with Risankizumab
by: Abdulmajeed Alajlan, et al.
Published: (2022-08-01)

A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab [Corrigendum]
by: Megna M, et al.
Published: (2024-06-01)

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
by: Potestio L, et al.
Published: (2023-08-01)

Bullous Pemphigoid Associated with Erythrodermic Psoriasis: A Case Report
by: Chen W, et al.
Published: (2022-09-01)

Ixekizumab: an alternative for HIV-positive psoriasis patients
by: Fanghua Liu, et al.
Published: (2024-11-01)

Treatment of Erythrodermic Psoriasis in Children with Secukinumab: A Case Report
by: Lu X, et al.
Published: (2023-07-01)

A nomogram diagnostic cardiovascular disease in patients with erythrodermic psoriasis in Chinese
by: Yue-Min Zou, et al.
Published: (2023-06-01)

Efficacy and Safety of Adalimumab and Secukinumab in Erythrodermic Psoriasis: A Single Centre Retrospective Study
by: Yachen Wang, et al.
Published: (2025-07-01)

Erythrodermic Psoriasis with Superimposed Fungal Infection-a Presentation in the Emergency Room
by: Muhammad Akbar Baig, et al.
Published: (2018-03-01)

Ustekinumab Treatment of Erythrodermic Psoriasis Occurring after Physical Stress: A Report of Two Cases
by: Rosita Saraceno, et al.
Published: (2013-09-01)

Efficacy and Safety of Oxymatrine in the Treatment of Patients with Erythrodermic Psoriasis
by: Huijuan Shi, et al.
Published: (2024-05-01)

Ustekinumab Efficacy and Safety in Children with Plaque, Erythrodermic and Palmoplanar Forms of Psoriasis: Retrospective Cohort Study
by: Nikolay N. Murashkin, et al.
Published: (2020-12-01)

Efficacy and safety of ixekizumab versus adalimumab in patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomised SPIRIT-H2H trial
by: Kristian Reich, et al.
Published: (2022-05-01)

Long-term management of pediatric psoriasis with ixekizumab: a case report
by: Diego Orsini, et al.
Published: (2023-12-01)

Efficacy and safety of biologics in erythrodermic psoriasis: a systematic review and single-arm meta-analysis
by: Lingjie Gao, et al.
Published: (2025-10-01)

Ustekinumab is effective and safe in the long‐term treatment of erythrodermic psoriasis: Multicenter study in daily practice
by: Clara Plana, et al.
Published: (2024-06-01)

Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q)
by: Jennifer Soung, et al.
Published: (2023-06-01)

Ixekizumab
by: İlgen Ertam Sağduyu
Published: (2022-04-01)

Severe Generalized Pustular Psoriasis Successfully Treated with Ixekizumab: A Case Report
by: Martina Burlando, et al.
Published: (2022-11-01)

Respiratory Distress Syndrome Associated with Erythrodermic Psoriasis
by: Lamya Noure, et al.
Published: (2021-02-01)

Prevalence of Metabolic Syndrome in Chinese Patients With Erythrodermic Psoriasis: A Case-Control Study
by: An-ran Ma, et al.
Published: (2021-12-01)

A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
by: Bruce W. Kirkham, et al.
Published: (2023-07-01)

Heart failure in erythrodermic psoriasis: a retrospective study of 225 patients
by: Chao Wu, et al.
Published: (2023-08-01)

Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes
by: Luís Puig, et al.
Published: (2019-08-01)

Efficacy and Safety of Bimekizumab in Japanese Patients with Generalised Pustular Psoriasis and Erythrodermic Psoriasis: 3-Year Results from BE BRIGHT, a Multicentre, Open-Label, Phase 3 Study
by: Yukari Okubo, et al.
Published: (2025-08-01)

Update on Erythrodermic Psoriasis: Proposal of a Management Algorithm by an Innovative Severity Evaluation Approach
by: Xu JM, et al.
Published: (2025-07-01)

Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program
by: Alice B. Gottlieb, et al.
Published: (2023-07-01)

Erythrodermic Psoriasis in the Context of Emerging Triggers: Insights into Dupilumab-Associated and COVID-19-Induced Psoriatic Disease
by: Aya Fadel, et al.
Published: (2025-06-01)

Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab
by: Blauvelt A, et al.
Published: (2020-03-01)

Possible effects of anti-interleukin-17 agents on erythrodermic psoriasis with thymoma: A case report
by: Qiuyu Jia, MD, PhD, et al.
Published: (2025-10-01)

Ixekizumab trough concentrations in psoriasis: Paving the way towards personalised therapy: A cohort study
by: Lisa Schots, et al.
Published: (2024-12-01)

Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3
by: Alexander Egeberg, et al.
Published: (2022-10-01)

Successful Treatment with Secukinumab in an Erythrodermic Psoriasis Patient with End-Stage Kidney Disease on Hemodialysis: A Case Report
by: Zhang S, et al.
Published: (2025-10-01)

The Age Factor in Ixekizumab Survival: Older Patients Show Higher Long-Term Treatment Survival
by: Inés Noval-Martín, et al.
Published: (2025-10-01)

Ixekizumab as a successful treatment in pediatric generalized pustular psoriasis
by: Maria Esposito, et al.
Published: (2025-02-01)

Clinical experience of using Ixekizumab in treatment of a female patient with severe psoriasis and psoriatic arthritis, resistant to the therapy
by: N. V. Kungurov, et al.
Published: (2021-06-01)